Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has successfully developed a variety of anti-CD30-related products to meet your exact project requirements.
CD30, known as TNFRSF8, is a transmembrane protein expressed on the cell surface as a protein receptor with a 120 kDa molecular weight. Several studies have identified that CD30 plays a number of key roles in lymphocyte activation and survival, as well as in the regulation of immune responses. More importantly, CD30 is associated with the progression of various cancers, such as T-cell lymphoma, anaplastic large-cell lymphoma, and Hodgkin lymphoma. Nowadays, CD30 is a promising target for CART therapy.
Fig.1 Schematic representation of CD30 molecule in the intracellular signaling pathway.1
Anti-CD30 CAR-T Proliferation Test
To assess the amplification potential of CART cells, Creative Biolabs successfully developed accurate and robust CART proliferation assay services to aid in CART development. We offer several approaches for global clients to perform CART proliferation assay smoothly, such as cell vitality real-time monitoring.
Fig.2 Total cell proliferation test of anti-CD30 CAR T-cells after CD30-CAR transduction (second-generation CD30-28z CAR and third-generation CD30-28BBz CAR).2
Anti-CD30 CAR-T Phenotype Characterization
To evaluate intracellular signal transduction in CART cells, we have developed various T cell subtype and phenotype analysis services to study T cell subpopulation distribution, T cell activity, and exhaustion function by flow cytometry.
Fig.3 Phenotype analysis of second-generation and third-generation Anti-CD30 CAR T-cells by flow cytometry.2
Anti-CD30 CAR-T Expression Test
To detect antigen-specific CAR expression, Creative Biolabs provides comprehensive approaches (such as qPCR, flow cytometry, WB), as well as extensive CAR detection reagents (anti-Fab antibodies, anti-G4S linker antibodies) to support customers' special needs.
Fig.4 Flow cytometry analysis of CD30 CAR expression on second-generation and third-generation Anti-CD30 CAR T-cells after CD30-CAR lentivirus transduction.2
Anti-CD30 CAR-T Cytokine Release Test
To help global clients speed CART development, Creative Biolabs is committed to providing a comprehensive range of cytokine analysis services by various methods, such as ELISA, ELISPOT, and multiplex cytokine array.
Fig.5 Cytokine production analysis (IFNγ and IL-6) in second-generation and third-generation Anti-CD30 CAR T-cells co-cultured with CD30+L428 cells or CD30-Raji cells.2
Anti-CD30 CAR-T In Vitro Cytotoxicity Assay
In the CART development, CART anti-tumor activity validation is a necessary step to detect the effectiveness of CART cells. Leveraging our advanced technology platforms, we offer highly sensitive CAR-T cell cytotoxicity assay services to help global clients validate the targeted effectiveness of CAR-T products.
Fig.6 Cytotoxicity of second-generation and third-generation CD30 CAR T-cells against 3 different tumor target cells at indicated E:T ratio.2
Efficacy Test of Anti-CD30 CAR-T
Meanwhile, Creative Biolabs specializes in providing extensive mouse models and comprehensive in vivo anti-tumor assay services to evaluate the efficacy of CAR-T cells.
Fig.7 In vivo anti-tumor evaluation of second-generation and third-generation CD30 CAR-T in the CD30+L428 xenograft model. (Zhang, et al., 2022).2
Toxicity Evaluation Anti-CD30 CAR-T
CAR-T cell therapy-associated toxicity remains challenging in CART studies. The evaluation of toxicity and safety has been a crucial step in CART development. At Creative Biolabs, we provide several robust in vivo assay services for toxicity evaluation and safety assessment of CAR-T cell therapy, including on-target, and off-target toxicity studies, and CRS management.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-SB-LX0090 | Anti-CD30 (CAC10) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | CAC10 | Human | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0091 | Anti-CD30 (HRS4) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | HRS4 | Human | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-YF17 | TS-Fluc Anti-Human CD30 scFv (HRS3) CD28-CD3ζ CAR, pCDCAR1 | Human | HRS3 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF77 | TS-Fluc Anti-Human CD30 scFv (HRS3) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | HRS3 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF78 | TS-Fluc Anti-Human CD30 scFv (5F11) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | 5F11 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF79 | TS-Fluc Anti-Human CD30 scFv (Brentuximab) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | Brentuximab | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF80 | TS-Fluc Anti-Human CD30 scFv (SGN-30) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | SGN-30 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF137 | TS-Fluc Anti-Human CD30 scFv (HRS3) CD28-4-1BB-CD3ζ CAR, pCDCAR1 | Human | HRS3 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF138 | TS-Fluc Anti-Human CD30 scFv (5F11) CD28-4-1BB-CD3ζ CAR, pCDCAR1 | Human | 5F11 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF200 | TS-IL15 SA Anti-Human CD30 scFv (SGN-30) CD28-CD3ζ CAR, pCDCAR1 | Human | SGN-30 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF257 | TS-IL15 SA Anti-Human CD30 scFv (HRS3) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | HRS3 | Human | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF319 | TS-IL15 SA Anti-Human CD30 scFv (Brentuximab) CD28-4-1BB-CD3ζ CAR, pCDCAR1 | Human | Brentuximab | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF320 | TS-IL15 SA Anti-Human CD30 scFv (SGN-30) CD28-4-1BB-CD3ζ CAR, pCDCAR1 | Human | SGN-30 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-YF438 | TS-NKG2DL Anti-hCD3 and Anti-Human CD30 scFv (5F11) 4-1BB-CD3ζ CAR, pCDCAR1 | Human | 5F11 | Human | 7H-YB-NKG2DL Anti-hCD3 and (OKT3 scFv-NKG2D ECD)-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0823-LX16 | Anti-hCD30 (RS3) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | RS3 | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
